June 20, 2011
5:00 - 8:00 pm
Are you ready to move your genomic-based technology from the bench to the market? Planning is important for advancement in this current economic climate.
Scientifically, as a result of the NGS explosion, genome analysis has undergone a revolution in recent years. Economically, U.S. Healthcare will likely undergo significant shifts in the coming decade, brought on at least partly by the recent passage of the Health Care Act of 2010.
How will medical research and innovation adapt to a healthcare market increasingly focused on preventive medicine, outcome measurement and cost containment?
Should researchers now pursue projects with a greater awareness of the economics of healthcare delivery?
Will we see an increased emphasis on early diagnostic technologies leading to both cheaper and better outcomes?
How will such innovation and risk be compensated?
What innovations will be more likely to get funded in the coming years?
The Business of Genomics: Planning Now to Survive and Thrive dinner short course program features dynamic presentations, elevator pitches, and interactive discussions relevant to both the scientific and business community. Presentations to the venture capitalists include:
Cost-Effective Strategies for Large-Scale, Massively-Parallel Sequencing of the Mitochondrial DNA Genome
Steve Carr, Ph.D., Co-Founder, Carr & Marshall 2001
Carr & Marshall 2001 Genetic Consultants, Inc. is a two-person consulting firm with broad experience in biotechnology applications to genetic and genomic biodiversity. We pioneered the use of PCR and automated dideoxy DNA sequencing techniques to academic and applied questions of population genetics and fisheries stock identification. This is now being extended to NextGen genomic methods for large-scale population analysis through iterative microarray re-sequencing (the “ArkChip”) of complete mtDNA genome sequences. We seek to promote awareness and use of high-throughput, massively-parallel, multi-species approaches for applied problems in long-term, large-scale biodiversity.
Navigating Genetic Data Regulation, Privacy, and Ease of Use
Alice Rathjen, President & Founder, DNA Guide, Inc.
Founded in 2009, DNA Guide provides a platform for managing genetic information for all users navigating genetic data regulation, privacy and utility. Our solution addresses the three key barriers to growth for the genetic information marketplace: genetic data regulation, genetic data security and genetic data and information format that makes it accessible to wider audiences. The application leverages geographic information systems (GIS) technology to distribute dynamic maps of entire genomes on mobile platforms. The total solution offers a mechanism to facilitate the exchange of genetic information from the lab to the health services setting, with the ability to engage the patient as well.
Low Cost, Companion Genetic Testing for Therapeutics and Public Health Screening
Michael Hogan, Ph.D., Co-Founder, CSO & Chairman, Scientific Advisory Board, GMS Biotech
The GMS approach to Companion Genetic Testing is similar to serology in that samples can be analyzed, as-is, without extraction. GMS is launching its core technology – low-cost microarray testing on raw samples – as a radically-simplified way to analyze the principle components of the human immune system: the 6 HLA genes. A suite of “HLA-Chips” and companion software have been developed as our first products. Our mission is to develop a new standard for HLA-typing that is inexpensive enough to be a companion test for vaccination, or small-molecule therapy, or as a public health screening test for childhood disease risk while being accurate enough to be the companion genetic test for organ and stem cell therapy.
Science and Technology: Hear from entrepreneurial academics, start-ups and early-stage companies showcasing their genomic-based ventures focused on:
Funding Fundamentals: Learn from a Venture Capitalist panel making investments for the next innovations in healthcare.
The instructional dinner includes elevator presentations from selected entrepreneurs followed by a VC panel critique in the light of the present healthcare economic reality.
Who Should Attend: Academic Entrepreneurs, Principle Investigators (PIs), Start-Up and Early-Stage Company CEOs/CSOs. Decision makers and experts in licensing, alliance management, business development, strategic planning, technology evaluation, technology transfer, and portfolio management. Capital funding firms including venture capitalists, public & private investors, government funding agencies, corporate governance, incubators, and technology transfer centers.
The interactive dinner concludes with networking opportunities, allowing participants to connect over coffee and dessert.
Who Should Submit a Proposal: Academic Entrepreneurs, Principle Investigators (PIs), Start-Up and Early-Stage Company CEOs
To ensure the quality of the program, all proposals will be reviewed by the advisory committee. This elite panel of high-profile experts will select the most intriguing and promising technologies and companies to present. The selected participants must register for the short course dinner to present.
The Business of Genomics: Planning Now to Survive and Thrive will take place on the following date:
For more details on the course, please contact:
Mary Ann Brown,
Executive Director, Conferences
Cambridge Healthtech Institute
T: (+1) 781-972-5497
E: mabrown@healthtech.com
For sponsorship information, please contact:
Stacey Squatrito
Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 508-579-3378
E: ssquatrito@healthtech.com